{"id":"be-pep-rifampicin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Drug-drug interactions"}]},"_chembl":{"chemblId":"CHEMBL374478","moleculeType":"Small molecule","molecularWeight":"822.95"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rifampicin is a well-established bacterial RNA polymerase inhibitor that disrupts mycobacterial transcription. BE-PEP (Bioavailability Enhancement Peptide) technology is applied to rifampicin to enhance its oral absorption and pharmacokinetic properties, potentially allowing for improved efficacy and simplified dosing regimens in tuberculosis therapy.","oneSentence":"BE-PEP Rifampicin is a rifampicin-based formulation designed to improve bioavailability and reduce dosing frequency for tuberculosis treatment.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:03:45.345Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tuberculosis (pulmonary and extrapulmonary)"}]},"trialDetails":[{"nctId":"NCT03662022","phase":"PHASE3","title":"Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2019-01-02","conditions":"Leprosy","enrollment":144000},{"nctId":"NCT05406479","phase":"PHASE2","title":"Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy (Phase 2)","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2022-07-14","conditions":"Leprosy","enrollment":313},{"nctId":"NCT05597280","phase":"PHASE3","title":"Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy","status":"RECRUITING","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2023-03-22","conditions":"Leprosy","enrollment":124000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BE-PEP Rifampicin","genericName":"BE-PEP Rifampicin","companyName":"Institute of Tropical Medicine, Belgium","companyId":"institute-of-tropical-medicine-belgium","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BE-PEP Rifampicin is a rifampicin-based formulation designed to improve bioavailability and reduce dosing frequency for tuberculosis treatment. Used for Tuberculosis (pulmonary and extrapulmonary).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}